LZTS2, leucine zipper tumor suppressor 2, 84445

N. diseases: 22; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.300 GeneticVariation disease UNIPROT
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.300 GeneticVariation disease UNIPROT
CUI: C1335051
Disease: Non-Neoplastic Urinary System Disorder
Non-Neoplastic Urinary System Disorder 		0.200 Biomarker disease MGD
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 PosttranslationalModification group BEFREE The qMSP analyses revealed that LZTS2 promoter methylation levels in the LSCC tumor samples were significantly higher than those in paired adjacent healthy tissue samples. 29499699 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE The leucine zipper tumor suppressor 2 (LZTS2) was identified as a tumor susceptibility gene within the 10q24.3 chromosomal region, and is approximately 15Mb from the PTEN locus. 28323888 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE In conclusion, our results demonstrate the critical role of miR-300 in GSLCs and its functions in LZTS2 inhibition and describe a new approach for the molecular regulation of tumor stem cells. 24464870 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 GeneticVariation group BEFREE These data provide the first line of evidence demonstrating that deletion of Lzts2 increases susceptibility to spontaneous and carcinogen-induced tumor development. 23275340 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 AlteredExpression group BEFREE We found that low levels of LZTS2 in NSCLC were correlated with tumor and nodal status. 23761130 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown. 17351128 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 PosttranslationalModification group BEFREE The LZTS2 gene is located at 10q24.3, which is frequently lost in a variety of human tumors. 17000760 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. 11709705 2001
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE LZTS2 (leucine zipper tumor suppressor 2), a candidate tumor suppressor gene, suppresses cell growth and plays a vital role in the carcinogenesis and development of tumors. 29499699 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE Functionally, we showed that LZTS2 suppresses tumorigenesis and radioresistance in nasopharyngeal carcinoma in a p85-dependent manner. 29409973 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE These data demonstrate the significance of simultaneous Pten and Lzts2 deletion in oncogenic transformation in prostate cells and implicates a new mechanism for the dysregulation of Wnt/β-catenin signaling in prostate tumorigenesis. 28323888 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE Using an Lzts2 knock-out mouse model, we characterized the biological role of Lzts2 in tumorigenesis. 23275340 2013
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 AlteredExpression disease BEFREE Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription. 28323888 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 AlteredExpression disease BEFREE Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription. 28323888 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 AlteredExpression disease BEFREE Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells. 23275340 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 AlteredExpression disease BEFREE Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells. 23275340 2013
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 Biomarker disease BEFREE LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown. 17351128 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 Biomarker disease BEFREE LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown. 17351128 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 Biomarker group BEFREE These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer. 17351128 2007
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer. 17351128 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 Biomarker group BEFREE Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer. 11709705 2001
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer. 11709705 2001